Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Immunexpress Looks To Leverage U.S. Anti-Infection Incentives With Unique Sepsis Diagnostic

This article was originally published in The Gray Sheet

Executive Summary

The Seattle company's SeptiCyte system is designed to directly quantify molecular markers of sepsis from patient blood samples and tell doctors the probability that a patient has sepsis within four hours, allowing for aggressive treatment of sepsis or, if the test result is negative, preventing unnecessary antibiotics.

You may also be interested in...



Battling Infection: Hospitals Seek High-Tech Solutions

The market for diagnostic and infection control products will see continued growth as hospitals and other providers look to the technology sector to help fight the battle against health care-associated infections and antibiotic-resistant organisms.

“Never Events” Spur Medical Device Innovation

Start-ups developing technologies to help hospitals avoid preventable medical errors known as “never events” are developing solutions to nosocomial infections, retained surgical objects, pressure ulcers, and medication errors.

Purell Battling Class Actions Over Disease Claims While World Scrambles To Increase Hand Sanitizer Supplies

Leading chemical firms, beauty and consumer health companies, even distilleries and medical marijuana cultivators are adapting operations to meet global demand for hand sanitizers amid the COVID-19 pandemic. Meanwhile, plaintiff’s attorneys are busy with multiple class actions against Purell manufacturer GOJO Industries for alleged false advertising following a January warning letter to the firm from the US FDA.

UsernamePublicRestriction

Register

MT033944

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel